City
Epaper

Will take 12-18 months to develop vaccine for coronavirus: Mark Esper

By ANI | Updated: March 18, 2020 07:11 IST

US Secretary of Defense Mark Esper said in a press briefing on Tuesday that the Department of Defense believes it will take 12 to 18 months to develop a vaccine for the novel coronavirus (COVID-19).

Open in App

Washington D.C. [US], Mar 18 (Sputnik/): US Secretary of Defense Mark Esper said in a press briefing on Tuesday that the Department of Defense believes it will take 12 to 18 months to develop a vaccine for the novel coronavirus (COVID-19).

"Twelve to eighteen months, the normal course," Esper said when asked how long it will take the Defense Department to develop a vaccine for COVID-19.

Esper noted that some private firms believe they can develop a vaccine quicker than the US military's timeline.

He added that if a private firm engages to develop a vaccine, the Defense Department may be able to provide additional support.

As of Tuesday, the COVID-19 virus has infected more than 195,000 people around the world in over 150 countries and killed more than 7,800 people. (Sputnik/)

( With inputs from ANI )

Tags: Defense DepartmentDepartment Of Defense
Open in App

Related Stories

InternationalUS announces additional USD 500 million security assistance package for Ukraine

InternationalUS announces additional military aid of USD 1.2 billion for Ukraine

PoliticsUS announces additional arms aid worth $325 mn for Ukraine

InternationalUSD 842 billion budget proposal for US defence driven by competition with China: Austin

InternationalUS military shoots down high-altitude object over Lake Huron

International Realted Stories

InternationalDonald Trump warns US military officials of 'invasion' within country

InternationalPakistan: 10 suspected robbers killed in five encounters in Punjab

InternationalEarthquake of magnitude 3.6 jolts Myanmar

InternationalPakistan government hikes prices of petrol and diesel, new rates effective immediately

InternationalTrump signs executive order to accelerate pediatric cancer research